NealHermanowiczMD

Neurology • Rancho Mirage, CA

Movement Disorder

Neurology, Christus- St. Vincent Medical Center, Sanat Fe, NM

Join to view full profile

Dr. Hermanowicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hermanowicz's full profile

Already have an account?

Office
39000 Bob Hope Dr.
Probst Bldg., Ste. 311
Rancho Mirage, CA 92270
Phone+1 760-837-8785

Education & Training

University of MichiganFellowship, Neuromuscular Medicine (Neurology), 1989 - 1991
University of Wisconsin Hospitals and ClinicsChief Residency, Neurology, 1988 - 1989
U Wisconsin Hospital and Clinics1986 - 1989
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1985 - 1986
Lewis Katz School of Medicine at Temple UniversityClass of 1985
University of Illinois at Urbana-ChampaignBS, Chemistry, 1972 - 1976

Certifications & Licensure

CA State Medical License 1997 - 2026
NM State Medical License 1991 - 2025
IL State Medical License 1996 - 1999
MI State Medical License 1989 - 1993
WI State Medical License 1986 - 1989
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Orange County Physician of Excellence Orange County Medical Association with Orange Coast Magazine, 2006, 2007, 2010, 2006-2018
Best Doctor, Neurology Best Doctors, Inc., 2013-2017
Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:LA Area Castle Connolly, 2013
Palm Springs Life Magazine Castle Connolly, 2006-2013
Top Doctors:Southern California Castle Connolly, 2012
Faculty Teaching University of California, Irvine, 2008
Faculty Appreciation University of California, Irvine, 2005
Pioneer Hall of Fame University High School Normal, Illinois, 2004
Dystonia Doctor of Excellence San Diego County Support Group of the Dystonia Medical Research Foundation, 2003
Lamport Award for Medical Student Research Temple University School of Medicine, 1983
Clinical Excellence Evanston Hospital-Northshore University Healthsystem, 1977
Bachelor of Science with Highest Distinction in the Chemistry University of Illinois, 1976
Phi Lambda Upsilon The National Honorary Chemical Society University of Illinois, 1975
Phi Kappa Phi, Honor Society University of Illinois, 1975
Physician of Excellence US News/Castle Connolly/Palm Springs Life Magazine, 2007-2012
President Orange County Neurological Society, 1998-2000
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain Start of enrollment: 2005 Apr 01
Unknown status
Not Applicable
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Terminated
Phase 3
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease Start of enrollment: 2017 Apr 27
Completed
Phase 2
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) Start of enrollment: 2018 Oct 17
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson's Disease: A PMD Alliance Survey.
Neal Hermanowicz, Maria Cristina Ospina, Yasar Torres-Yaghi, Sherrie Gould, Kelly Papesh
Neuropsychiatric Disease and Treatment. 2022-01-01
17 citations
Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase–Associated Neurodegeneration
Thomas Klopstock, Aleksandar Videnovic, Almut Turid Bischoff, Cecilia Bonnet, Laura Cif
Movement Disorders. 2021-06-01
Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections.
Neal Hermanowicz
Case Reports in Neurology. 2021-01-01

Journal Articles

Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.
Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T, BMC Med Genet. 2010 Apr 1;11:53
Clinical correlates of depressive symptoms in familial Parkinson's disease.
Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study Group-PROGENI Investigators, Mov Disord. 2008 Nov 15;23(15):2216-23
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM; Istradefylline 6002-US-013 Study Group, Mov Disord. 2008 Nov 15;23(15):2177-85
PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for susceptibility genes contributing to familial P...
Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, Hum Genet. 2009 Jan;124(6):593-605
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset.
Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T; Parkinson Study Group-PROGENI Investigators, Neurology. 2009 Jan 27;72(4):310-6
Variation in GIGYF2 is not associated with Parkinson disease.
Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Neurology. 2009 Jun 2;72(22):1886-92
Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.
Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, Neurology. 2009 Jul 28;73(4):279-86
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, Mov Disord. 2009 Oct 30;24(14):2081-90
Genomewide association study for onset age in Parkinson disease.
Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T; PROGENI Investig..., BMC Med Genet. 2009 Sep 22;10:98
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, N Engl J Med. 2009 Sep 24;361(13):1268-78
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, Mov Disord. 2009 Dec 15;24(16):2370-8
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr, Arch Neurol. 2010 Mar;67(3):347-52
Parkinson's Rasagiline: Efficacy and Safety in the Treatment of Off Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibi...
White WB, Salzman P, Schwid SR, Hypertension. 2008 Sep;52(3):587-93
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, Cephalalgia. 2010 Jul;30(7):793-803
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kiebu..., Mov Disord. 2010 Sep 15;25(12):1801-8
A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Trv?ster AI, Uc EY, Mov Disord. 2010 Nov 15;25(15):2501-7
A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY, Mov Disord. 2010 Nov 15;25(15):2501-7
Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE, Mov Disord. 2011 Mar;26(4):608-13
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S, J Neurol Sci. 2011 Sep 15;308(1-2):103-9
Copy number variation in familial Parkinson disease.
Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL, PLoS One. 2011;6(8):e20988
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's di...
Lew MF, Somogyi M, McCague K, Welsh M, Int J Neurosci. 2011 Nov;121(11):605-13
Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2.
Pankratz N, Beecham GW, Destefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER,..., Ann Neurol. 2012 Mar;71(3):370-84
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.
Wray S, Self M; NINDS Parkinson's Disease iPSC Consortium; NINDS Huntington's Disease iPSC Consortium, et al, PLoS One. 2012;7(8)
Genome-Wide Linkage Analysis and Evidence of Gene-by-Gene Interactions in a Sample of 362 Multiplex Parkinson Disease Families.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group, Human Molecular Genetics 2003;12:2599-2608
Abnormal membrane methylation and merocyanine 540 fluorescence in sickle cell erythrocyte membranes.
Manna C., Hermanowicz N, Ro J.Y., Neilan B., Glushko V., Kim S, Biochemical Medicine, 1984; 31: 362-370
Join now to see all

Books/Book Chapters

Textbook of Clinical Neurology.
Chapter: Cranial Nerves IX (Glossopharyngeal) and X (Vagus)
Page 211 - 222Hermanowicz NEditors: Goetz CG.Elsevier, Philadelphia
Encyclopedia of Movement Disorders.
Chapter: Hemiballismus
Page 14 - 17Hermanowicz NEditors: Kompoliti K and verhagen L.Elsevier, Philadelphia

Lectures

Parkinson’s disease: new directions.
Salt Lake City Parkinson’s disease organization
Cervical dystonia: Diagnosis and treatment.
Asia-Oceanian Conference for Physical and Rehabilitative Medicine. Nanjing, China
Dementia and Parkinson’s disease.
Orange County Alzheimer’s Disease Association Annual Symposium. Irvine, CA
Huntington’s disease. Frontiers of the Mind.
University of California, Irvine
Unusual Movement Disorders.
The Brain and Spine Forum, Huntington Hospital. Pasadena, CA
Join now to see all

Press Mentions

What Every Family Needs to Know About Parkinson’s DiseaseOctober 24th, 2019
Caltech Study Finds Link Between Parkinson's Disease and Gut BacteriaDecember 1st, 2016
What to Ask Your Doctor About Parkinson’s DiseaseFebruary 17th, 2018